Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.

What the trial testedrandomised · 492 people · 2016

Randomised comparison

−0.20−0.39 to −0.01

As reported

difference −0.20, 95% CI −0.39 to −0.01

the abstract, start to end

… [least squares mean difference: -0.20; 95% confidence interval (CI) …

← favours treatmentfavours comparator →

could be chance

Glycemic control

−0.20−0.39 to −0.01

GLP-1 receptor agonistsGlycemic control

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely

0.910.91 without it

← favours treatmentfavours comparator →

this papermore certainless certain

1 / 5

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

this paperpooled ittrialcites it